×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EXEL – exelixis, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EXEL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/7
11:58 am
exel
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Guggenheim from $33.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Guggenheim from $33.00 to $42.00. They now have a "buy" rating on the stock.
1/6
04:30 pm
exel
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [Yahoo! Finance]
Low
Report
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [Yahoo! Finance]
1/6
04:05 pm
exel
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
Medium
Report
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
12/27
11:24 am
exel
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
12/25
01:54 pm
exel
EXEL vs. INCY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]
Low
Report
EXEL vs. INCY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]
12/23
10:31 am
exel
Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024? [Yahoo! Finance]
Low
Report
Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024? [Yahoo! Finance]
12/23
08:00 am
exel
Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Brookline Capital Management. They set a "buy" rating on the stock.
Low
Report
Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Brookline Capital Management. They set a "buy" rating on the stock.
12/20
08:22 am
exel
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/23
08:17 pm
exel
Form 4 EXELIXIS, INC. For: Dec 20 Filed by: MORRISSEY MICHAEL
Low
Report
Form 4 EXELIXIS, INC. For: Dec 20 Filed by: MORRISSEY MICHAEL
12/2
08:29 pm
exel
Form 4 EXELIXIS, INC. For: Nov 27 Filed by: Hessekiel Jeffrey
Low
Report
Form 4 EXELIXIS, INC. For: Nov 27 Filed by: Hessekiel Jeffrey
11/29
01:13 pm
exel
Form 144 EXELIXIS, INC. Filed by: Hessekiel Jeffrey
Neutral
Report
Form 144 EXELIXIS, INC. Filed by: Hessekiel Jeffrey
11/26
07:06 pm
exel
Form 4 EXELIXIS, INC. For: Nov 22 Filed by: Haley Patrick J.
Low
Report
Form 4 EXELIXIS, INC. For: Nov 22 Filed by: Haley Patrick J.
11/22
04:02 pm
exel
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
Low
Report
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
11/19
08:04 pm
exel
Form 4 EXELIXIS, INC. For: Nov 15 Filed by: Senner Christopher J.
Low
Report
Form 4 EXELIXIS, INC. For: Nov 15 Filed by: Senner Christopher J.
11/19
08:04 pm
exel
Form 4 EXELIXIS, INC. For: Nov 15 Filed by: MORRISSEY MICHAEL
Low
Report
Form 4 EXELIXIS, INC. For: Nov 15 Filed by: MORRISSEY MICHAEL
11/19
08:03 pm
exel
Form 4 EXELIXIS, INC. For: Nov 15 Filed by: Peterson Amy C.
Low
Report
Form 4 EXELIXIS, INC. For: Nov 15 Filed by: Peterson Amy C.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/17
Form 4 EXELIXIS, INC. For: Apr 15 Filed by: SCANGOS GEORGE A
21.5%
6/20 Exelixis lower after IMspire170 fails to meet primary endpoint [Seeking Alpha] 9.0%
4/22 Form 4 EXELIXIS, INC. For: Apr 20 Filed by: Haley Patrick J. 7.6%
4/3 Form 4 EXELIXIS, INC. For: Apr 03 Filed by: WYSZOMIERSKI JACK L 6.7%
1/13 Form 8-K EXELIXIS, INC. For: Jan 12 6.6%
1/7 Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 6.1%
7/15 Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors 6.0%
11/13 Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 6.0%
4/21 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Barclays PLC. They now have a $30.00 price target on the stock. 5.6%
1/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $21.00 price target on the stock, down previously from $22.00. 4.9%
6/20 Exelixis lower after IMspire170 fails to meet primary endpoint [Seeking Alpha] 9.0%
4/22 Form 4 EXELIXIS, INC. For: Apr 20 Filed by: Haley Patrick J. 7.6%
4/3 Form 4 EXELIXIS, INC. For: Apr 03 Filed by: WYSZOMIERSKI JACK L 6.7%
1/13 Form 8-K EXELIXIS, INC. For: Jan 12 6.6%
1/7 Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 6.1%
7/15 Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors 6.0%
11/13 Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 6.0%
4/21 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Barclays PLC. They now have a $30.00 price target on the stock. 5.6%
1/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $21.00 price target on the stock, down previously from $22.00. 4.9%
TOP News Decliners
10/30
Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update
-14.9%
3/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at William Blair. -13.8%
1/24 Exelixis up 1% premarket on Cabometyx data in liver cancer [Seeking Alpha] -8.7%
7/31 Form 8-K EXELIXIS, INC. For: Jul 31 -6.5%
10/3 Form 4 EXELIXIS, INC. For: Oct 01 Filed by: Schwab Gisela -6.3%
4/9 Form DEF 14A EXELIXIS, INC. For: May 20 -5.2%
4/29 Form 4 EXELIXIS, INC. For: Apr 27 Filed by: MORRISSEY MICHAEL -5.0%
12/5 How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? [Yahoo! Finance News] -4.6%
3/10 Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript) [Seeking Alpha] -4.6%
12/6 Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) [Yahoo! Finance News] -4.5%
3/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at William Blair. -13.8%
1/24 Exelixis up 1% premarket on Cabometyx data in liver cancer [Seeking Alpha] -8.7%
7/31 Form 8-K EXELIXIS, INC. For: Jul 31 -6.5%
10/3 Form 4 EXELIXIS, INC. For: Oct 01 Filed by: Schwab Gisela -6.3%
4/9 Form DEF 14A EXELIXIS, INC. For: May 20 -5.2%
4/29 Form 4 EXELIXIS, INC. For: Apr 27 Filed by: MORRISSEY MICHAEL -5.0%
12/5 How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? [Yahoo! Finance News] -4.6%
3/10 Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript) [Seeking Alpha] -4.6%
12/6 Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) [Yahoo! Finance News] -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: